MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)
NCT: NCT05487612 · RECRUITING
Brief Summary
MiECS is one of the largest multicentre randomised controlled trials on extracorporeal circulation conducted under the auspices of Minimal Invasive Extracorporeal Technologies International Society (MiECTiS). It is designed to ultimately address the emerging effectiveness of MiECC systems in the light of modern perfusion practice worldwide. The primary hypothesis is that MiECC, as compared to conventional CPB (cCPB), reduces the proportion of patients experiencing serious perfusion-related postoperative morbidity after cardiac surgery. The study will be led by the Clinical Research Unit of the Special Unit for Biomedical Research and Education (SUBRE), Aristotle University of Thessaloniki School of Medicine in Greece (AUSoM) with Chief Investigator Professor Kyriakos Anastasiadis, who is a key-opinion-leader in the field of MiECC, founder and Executive Board of MiECTiS.
Frequently Asked Questions
What is MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)?
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS) is a clinical trial registered under NCT05487612. Current status: RECRUITING.
What is the status of NCT05487612?
The current status of NCT05487612 (MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS)) is: RECRUITING.
When did MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS) start?
MiECC Versus Conventional Cardiopulmonary Bypass in Cardiac Surgery (MiECS) started on 2022-05-26.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.